Tradestie Institutional Equity Comparison Engine
LYRA vs OBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
OBIO Overall Edge
OBIO Captures Institutional Edge (3โ0 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, LYRA trades at N/M Forward P/E with -25032.0% operating margin (-87.2% YoY revenue) versus OBIO at N/M Forward P/E and -195.4% operating margin (-89.4% YoY). In options structure, LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against OBIO sits in BREAKOUT (<1st %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
LYRA N/M vs OBIO N/M Fwd P/E
Growth & Margin Winner
OBIO
Op Margin -25032.0% vs -195.4% ยท YoY -87.2% vs -89.4%
Momentum & Technical Winner
OBIO
1Y -94.3% vs +78.2% ยท 52W Pos 1% vs 89%
Options & Structure Winner
OBIO
UNCLASSIFIED (N/A IV) vs BREAKOUT (<1st %ile IV)
LYRA
NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap
$2.3M
1M Return
-62.5%
1Y Return
-94.34%
Forward P/E
N/M
Unified AI Score
52.2 / 100
HOLD
Tech 60.0
Fund 56.0
Flow 50.0
Mom 59.0
OBIO
NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.02
-1.4% 1D
Market Cap
$570.6M
1M Return
+24.25%
1Y Return
+78.17%
Forward P/E
N/M
Unified AI Score
42.9 / 100
HOLD
Tech 15.0
Fund 40.0
Flow 62.0
Mom 44.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
LYRA -94.34%
OBIO +78.17%
Spread: +102.62 pp (OBIO Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LYRA Revenue | OBIO Revenue | LYRA Op. Margin | OBIO Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2021 | $0M | N/A | -15303.5% | N/A | LYRA |
| FY2022 | $0M | $0M | -4131.0% | -924.3% | OBIO |
| FY2023 | $0M | $0M | -4308.1% | -1866.2% | OBIO |
| FY2024 | $0M | $0M | -6280.8% | -2437.5% | OBIO |
| FY2025 | $0M | $30M | -7794.5% | -154.7% | OBIO |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LYRA | OBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.3M | $570.6M | Larger Scale | OBIO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -87.2% | -89.4% | Higher Growth | LYRA |
| Operating Margin (TTM) Profitability | -25032.0% | -195.4% | Higher Margin | OBIO |
| Net Profit Margin Profitability | 0.0% | -182.5% | Higher Margin | LYRA |
| Return on Equity (ROE) Capital Efficiency | -404.5% | -182.3% | Higher ROE | OBIO |
| 52-Week Range Position Momentum | 1% ($0โ$38) | 89% ($3โ$7) | Stronger Trend | OBIO |
| Beta / 30D Volatility Risk Regime | 0.33ฮฒ ยท 248% Vol | 1.15ฮฒ ยท 80% Vol | Lower Realized Risk | OBIO |
| Unified Institutional Score Composite Signal | 52.2 / 100 (HOLD) | 42.9 / 100 (HOLD) | Higher Composite | LYRA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full LYRA vs OBIO Buy Guide
LYRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
OBIO
BREAKOUT
33d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither LYRA nor OBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.